Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2016 August;64(4) > Minerva Cardioangiologica 2016 August;64(4):481-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

REVIEWS  NEW BIORESORBABLE TECHNOLOGY IN INTERVENTIONAL CARDIOLOGY 

Minerva Cardioangiologica 2016 August;64(4):481-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Bioresorbable vascular scaffold in patients with complex coronary artery disease

Claudia I. TAMBURINO, Piera CAPRANZANO, Giovanni LONGO, Sebastiano IMMÈ, Giacomo TAMBURINO, Matteo SCALIA, Antonio CONDORELLI, Bruno FRANCAVIGLIA, Alessio LA MANNA, Carmelo SGROI, Carmelo GRASSO, Maria E. DI SALVO, Davide CAPODANNO, Corrado TAMBURINO

University of Catania, Ferrarotto Hospital, Catania, Italy


PDF


The advent of fully bioresorbable stent technology is heralded as breakthrough technology in the current era of percutaneous coronary interventions (PCI). Bioresorbable scaffolds (BRS) have the potential to introduce a paradigm shift in interventional cardiology, representing an anatomical and functional “vascular restoration” therapy instead of an artificial stiff tube encased by persistent metallic foreign body. Among BRS, the everolimus-eluting scaffold (ABSORB, Abbott Vascular, Santa Clara, CA, USA) has been the most extensively investigated in clinical studies. The use of ABSORB in the treatment of relatively simple lesions appears to provide a similar degree of safety and efficacy compared with metallic drug-eluting stent (DES) treated under randomized trials conditions, but patients treated in real-world practice are far more complex than those included in randomized trials. Therefore, several ABSORB all-comers registries dealing with real world conditions are being performed. Their currently available results are summarized in the present overview.

inizio pagina